SII: Anti-cervical cancer vaccine

On July 12, 2022, the CEO of Serum Institute of India (SII) Adar Poonawalla announced company’s plans to roll out its indigenously-developed vaccine for the prevention of cervical cancer among women.


  • The Drugs Controller General of India (DCGI) has also accorded the market authorisation to SII for manufacturing the vaccine for cervical cancer.
  • It will be the first Quadrivalent Human Papillomavirus vaccine (qHPV) in India, to prevent cervical cancer.
  • DCGI accorded the market authorisation to SII, following the recommendation of Subject Expert Committee (SEC) of Central Drugs Standard Control Organization (CDSCO) on COVID-19 vaccine.
  • SII had filled to DCGI to get market authorization, after successful phase 2 & phase 3 of clinical trials. These trials were completed with the help of Department of Biotechnology.

Cervical cancer in India

Cervical cancer is the second most common cancers among women in India, even though it is preventable. This cancer is commonly diagnosed among women aged 15 to 44 years of age. According to Globocan 2020, cervical cancer stood at 9.4% of all cancers and 18.3% of new cancer cases in 2020. During 1990-2016, cervical cancer was the second main factor of cancer deaths for women across 12 Indian states.

National Cancer Control Programme (NCCP)

National Cancer Control Programme was first started in India in 1975. Under the programme, priorities were given to equip existing cancer hospital and institutions. Central assistance of Rs 2.50 lakhs was provided to each cancer institution, in a bid to purchase cobalt machines for radiotherapy.



Leave a Reply